Inventor · disambiguated record
Israel Rios
Also filed as: RIOS ISRAEL
1 granted patent·9 pending applications·1 citations·filing 2007–2011
17Inventor score
Top patents by PatentIndex Score
10 records- 0163US7906486B2Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosaSCICLONE PHARMACEUTICALS INC·Filed 2008·Granted Mar 15, 2011·1 cites·13 claims
- 0259US2008300166A1Treatment of Melanoma with Alpha Thymosin PeptidesSCICLONE PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 0354US2010016211A1Treatment of Melanoma With Alpha Thymosin PeptidesSCICLONE PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 0451US2010267637A1Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitorSCICLONE PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 0545US2011200558A1Treatment or Prevention of Hepatitis C with Immunomodulator CompoundsSCICLONE PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 0640US2010317583A1Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)SCICLONE PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 0740US2010330093A1Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)SCICLONE PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 0835US2011117211A1Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of MucosaSCICLONE PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 0934US2010197595A1Treatment of melanoma with alpha thymosin peptidesSCICLONE PHARMACETICALS INC·Filed 2010·Application pending·0 cites
- 1021US2011245316A1Prevention or delay of onset of oral mucositisSCICLONE PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Israel Rios files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →